Help shape the development of an action plan to eliminate cervical cancer

Participate in a nationwide survey by November 11, 2019

People of all genders aged 18 and over are encouraged to complete a short, confidential survey on cervical cancer prevention, screening, and treatment for a chance to win a $50 gift card. Your input will inform the development of an action plan to eliminate cervical cancer which will be released in 2020.

The Canadian Partnership Against Cancer is working with Malatest, an independent research company, to better understand Canadian attitudes and experiences related to cervical cancer, a disease that kills an estimated 410 women each year in Canada.

If the survey cannot be completed in one sitting, participants can save their answers and return to the survey using the unique access code provided at the bottom of the survey screen.

Take the survey

Frequently asked questions

  • The purpose of this survey is to engage the public and patients to inform the development of an action plan to eliminate cervical cancer in Canada. This is an ambitious goal but we are convinced that we can reach it with your help.
  • This survey has been commissioned by the Canadian Partnership Against Cancer (the Partnership). The Partnership is an independent, not-for-profit organization, funded by the Canadian government to accelerate action on cancer control for all Canadians.
    R.A. Malatest & Associates Ltd. (Malatest) is an independently-owned Canadian research company that has been in operation since 1985. Malatest has been contracted to undertake this survey on the Partnership’s behalf.
  • The Partnership is currently developing an action plan to eliminate cervical cancer in Canada, which will be published in 2020. Your participation will help the Partnership ensure that the action plan is informed by the perspectives and experiences of Canadians who may have experienced vaccination, screening and/or treatment for cervical cancer.
  • We are interested in hearing the perspectives of a wide range of Canadians to inform the action plan. As vaccination, screening and treatment for cervical cancer can affect anyone, regardless of gender, we want to hear from both men and women in their roles as citizens, parents, patients, survivors and caregivers.
  • Yes. Malatest is legally bound by their contract with The Partnership to treat all personal information provided with the highest standards of confidentiality. Malatest is also compliant with all provincial and territorial privacy legislation (e.g. Freedom of Information and Protection of Privacy Act, Access to Information and Protection of Privacy Act). In addition, Malatest will adhere to the regulations set out in Part 1 of the Personal Information Protection and Electronic Documents Act (PIPEDA). All of the data presented to the Partnership will be grouped and aggregated (according to privacy requirements).
    To further protect respondent’s privacy, Malatest has established a unique survey access code for each respondent. The internal database of survey results only includes this unique survey code and not any personal information.
  • If you would like to speak with someone about the survey, please contact Douglas Elliott, Senior Research Analyst at Malatest, by telephone at 1-800-665-5848 (extension 244) or by email at